$31.72 Million in Sales Expected for Evolus, Inc. (NASDAQ:EOLS) This Quarter

Wall Street brokerages expect Evolus, Inc. (NASDAQ:EOLS) to post $31.72 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Evolus’ earnings, with the highest sales estimate coming in at $32.70 million and the lowest estimate coming in at $30.50 million. Evolus reported sales of $20.58 million in the same quarter last year, which indicates a positive year-over-year growth rate of 54.1%. The firm is expected to issue its next quarterly earnings report on Wednesday, March 23rd.

On average, analysts expect that Evolus will report full-year sales of $96.73 million for the current fiscal year, with estimates ranging from $95.52 million to $97.70 million. For the next fiscal year, analysts anticipate that the firm will post sales of $154.79 million, with estimates ranging from $143.22 million to $163.55 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Evolus.

A number of research analysts recently commented on the stock. SVB Leerink reaffirmed a “buy” rating and issued a $18.00 price target on shares of Evolus in a report on Friday, November 12th. HC Wainwright lowered their price target on shares of Evolus from $22.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, November 3rd. Finally, Zacks Investment Research raised shares of Evolus from a “sell” rating to a “hold” rating in a report on Friday, November 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $14.72.

Shares of NASDAQ:EOLS traded up $0.05 during trading on Friday, reaching $6.06. The company’s stock had a trading volume of 319,461 shares, compared to its average volume of 890,560. Evolus has a 12 month low of $3.06 and a 12 month high of $17.38. The firm’s 50 day simple moving average is $7.49 and its two-hundred day simple moving average is $9.77. The stock has a market capitalization of $336.80 million, a PE ratio of -1.60 and a beta of 2.34.

In other Evolus news, major shareholder Alphaeon 1 Llc sold 2,597,475 shares of the firm’s stock in a transaction dated Thursday, September 2nd. The shares were sold at an average price of $9.50, for a total value of $24,676,012.50. Following the completion of the sale, the insider now owns 6,064,871 shares of the company’s stock, valued at $57,616,274.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.60% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the company. Federated Hermes Inc. increased its position in shares of Evolus by 302.9% during the second quarter. Federated Hermes Inc. now owns 152,112 shares of the company’s stock worth $1,924,000 after acquiring an additional 114,360 shares during the period. Stifel Financial Corp increased its position in shares of Evolus by 36.8% during the first quarter. Stifel Financial Corp now owns 52,523 shares of the company’s stock worth $682,000 after acquiring an additional 14,115 shares during the period. D. E. Shaw & Co. Inc. purchased a new position in shares of Evolus during the first quarter worth approximately $2,122,000. Squarepoint Ops LLC increased its position in shares of Evolus by 267.8% during the second quarter. Squarepoint Ops LLC now owns 47,928 shares of the company’s stock worth $606,000 after acquiring an additional 34,897 shares during the period. Finally, Marshall Wace LLP increased its holdings in Evolus by 82.2% during the second quarter. Marshall Wace LLP now owns 488,419 shares of the company’s stock valued at $6,178,000 after buying an additional 220,296 shares during the period. 40.74% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Read More: How does quantitative easing work?

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.